Clinical Trial Update: Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity [Phase 3]

View source ↗

Summary

A completed Phase 3 trial evaluating setmelanotide for early-onset POMC deficiency obesity has results posted, indicating late-stage evaluation completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pro-opiomelanocortin Deficiency Obesity

Drugs mentioned

• Setmelanotide (setmelanotide)

Snippet

Sponsor: Rhythm Pharmaceuticals, Inc. | Conditions: Pro-opiomelanocortin (POMC) Deficiency Obesity | Phase 3 | Status: COMPLETED | Results posted: 2023-09-21